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of TS gene (G>C); 6-bp deletion in 3′-UTR region of the 
TS (1494del6); 677C>T SNP in MTHFR; 19007C>T SNP 
in ERCC1. Molecular examinations’ results were correlated 
with disease control rate, progression-free survival (PFS) 
and overall survival.
Results Polymorphic tandem repeat sequence (2R, 3R) in 
the enhancer region of TS gene and G>C SNP within the 
second repeat of 3R allele seem to be important for the 
effectiveness of platinum and pemetrexed in first-line chem-
otherapy. The insignificant shortening of PFS in 3R/3R 
homozygotes as compared to 2R/2R and 2R/3R genotypes 
were observed, while it was significantly shorter in patients 
carrying synchronous 3R allele and G nucleotide. The com-
bined analysis of TS VNTR and MTHFR 677C>T SNP 
revealed shortening of PFS in synchronous carriers of 3R 
allele in TS and two C alleles in MTHFR. The strongest fac-
tors increased the risk of progression were poor PS, weight 
loss, anemia and synchronous presence of 3R allele and G 
nucleotide in the second repeat of 3R allele in TS. Moreo-
ver, lack of application of second-line chemotherapy, weight 
loss and poor performance status and above-mentioned gen-
otype of TS gene increased risk of early mortality.
Conclusion The examined polymorphisms should be 
accounted as molecular predictor factors for pemetrexed- 
and platinum-based front-line chemotherapy in non-squa-
mous NSCLC patients.
Keywords Non-small cell lung cancer · Pemetrexed · 
Platinum compounds · Gene polymorphisms
Introduction
Lung cancer is the main cause of death among all can-
cer patients in the world. Over 85 % of such cases are 
Abstract 
Purpose We presented retrospective analysis of up to 
five polymorphisms in TS, MTHFR and ERCC1 genes as 
molecular predictive markers for homogeneous Caucasian, 
non-squamous NSCLC patients treated with pemetrexed 
and platinum front-line chemotherapy.
Methods The following polymorphisms in DNA isolated 
from 115 patients were analyzed: various number of 28-bp 
tandem repeats in 5′-UTR region of TS gene, single nucleo-
tide polymorphism (SNP) within the second tandem repeat 
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represented by non-small cell lung cancer (NSCLC) and 
only 15 % of those cases have a chance of surgical resection 
(Dela Cruz et al. 2011). This is why systemic chemotherapy 
and radiotherapy are the main treatment options in NSCLC.
Standard first-line chemotherapy consisting of platinum 
compounds and drugs like gemcitabine or vinorelbine, used 
in NSCLC therapy, has proven to be effective, but at a cost 
of sometimes serious side effects (Sculier and Moro-Sibilot 
2009). Therefore, new 3rd generation drugs (pemetrexed) 
with lower toxicity profiles are being developed and used in 
combination with platinum compounds in first-line treatment 
of non-squamous NSCLC patients (Scagliotti et al. 2008).
Platinum compounds are the alkylating agents, which 
cross-link DNA in several different ways interfering with 
transcription and cell division. The damaged DNA elic-
its DNA repair mechanisms or activates apoptosis when 
repair proves impossible. Excision repair cross-comple-
menting group 1 (ERCC1) is an endonuclease, which is 
involved in DNA repair in nucleotide excision repair mech-
anism (NER). High expression of ERCC1 and other NER 
enzymes is associated with a high yield of DNA repair. 
Increased DNA repair is associated with longer survival of 
surgically treated patients, but is negative predictive factor 
for chemotherapy using platinum compounds (Zheng et al. 
2007; Gazdar 2007).
Pemetrexed is a novel cytostatic drug, which has shown 
efficacy in first and second line of treatment, as well as in 
maintenance therapy, of non-squamous NSCLC and malig-
nant pleural mesothelioma (Scagliotti et al. 2008, 2009; 
Al-Saleh et al. 2012). Pemetrexed is a multitarget antifolate 
agent that inhibits enzymes involved in pyrimidine and purine 
synthesis. Its main target is thymidylate synthase (TS). Inhi-
bition of TS results in decreased amount of thymidyne, which 
is necessary for DNA repair and synthesis. Pemetrexed also 
inhibits two other enzymes involved in purine/pyrimidine 
synthesis pathway: dihydrofolate reductase (DHFR) and gly-
cinamide ribonucleotide formyltransferase (GARFT). It is 
also known that the activity of those target enzymes alters the 
effectiveness of pemetrexed. High expression of TS, DHFR 
and GARFT in squamous cell lung cancer and some of lung 
adenocarcinoma was proven to reduce chemosensitivity of 
cancer cells to pemetrexed, and pemetrexed was inefficient 
in patients with this histologic subtype of NSCLC (Scagliotti 
et al. 2009; Chattopadhyay et al. 2007; Hanauske et al. 2007; 
Wang et al. 2014; Ceppi et al. 2006).
All three enzymes are folate dependent, and hence, the 
activity of pemetrexed also depends on cell folate level. It 
has been shown that increased levels of extracellular folates 
decreased pemetrexed activity in human lung and colon 
cancer cell lines (Chattopadhyay et al. 2007). Enzyme 
that is indirectly involved in the proper functioning of 
purine and pyrimidine synthesis pathway is 5,10-methyl-
enetetrahydrofolate reductase (MTHFR). It catalyzes an 
irreversible conversion of 5,10-methylenetetrahydrofolate 
(5,10-methyleneTHF) to methyltetrahydrofolate (5-methyl-
THF). Elevated levels of 5,10-methyleneTHF causes higher 
activity of TS and lower effectiveness of antifolate agents 
in cancers patients (Tiseo et al. 2012).
Thymidylate synthase mRNA level is regulated by three 
different polymorphisms: various number of 28-base-pair 
(bp) tandem repeats (VNTR) in 5′-UTR enhancer region 
of TS gene (TSER) (Mandola et al. 2003); a single nucleo-
tide polymorphism (SNP) G>C in the second repeat of 
28-bp repeats; and a 6-bp deletion on the 3′ end of the TS 
gene (1494del6) (Kawakami and Watanabe 2003; Uchida 
et al. 2004; Mandola et al. 2004; Stoehlmacher et al. 2009). 
VNTR and 1494del6 polymorphisms of TS gene are known 
to affect the effectiveness of 5-fluorouracil treatment of met-
astatic colorectal cancer and breast cancer patients (Dotor 
et al. 2006; Kumar et al. 2010). A polymorphism 677C>T in 
MTHFR gene was found to decrease the gene expression and 
hence to cause elevated levels of 5,10-methyleneTHF (Sohn 
et al. 2013). Several authors demonstrated that 19007C>T 
(Asn118Asn) polymorphism of ERCC1 gene is involved in 
ability to DNA repair. However, correlation between geno-
types of ERCC1 gene and the expression of ERCC1 protein 
in cancer cells is still controversial (Mlak et al. 2013).
In our retrospective, non-randomized, multicenter 
study, we tried to assess the usefulness of TS, MTHFR and 
ERCC1 genes polymorphisms detected in venous blood 
cells as molecular predictive markers for first-line pem-
etrexed and platinum therapy in NSCLC patients.
Materials and methods
The studied group consisted of 115 non-squamous NSCLC 
patients treated with pemetrexed in combination with plati-
num compounds (cisplatin in 108 patients, carboplatin in 7 
patients). All patients have been verified pathomorphologi-
cally and staged by computed tomography. Medical history 
data of each patient were collected. Patients’ performance 
status was assessed according ECOG-WHO score. Patients 
were qualified for the therapy between 2008 and 2012 year. 
About 500 mg/m2 of pemetrexed was administered as an 
intravenous infusion on day 1 of each 21 day cycle. Cispl-
atin 75 mg/m2 infused over 2 h beginning approximately 
30 min after the end of the pemetrexed administration. 
Carboplatin was dosed according to New Guidelines for 
Carboplatin Dosing. To reduce toxicity, patients were pre-
treated with folic acid and B12 vitamin. Clinical character-
istic of patients is presented in Table 1.
Response to chemotherapy has been described according 
to RECIST criteria. During observation period (2008–Feb-
ruary 2014), progression was observed in 85 patients and 
57 patients died (complete observations).
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Blood samples of examined patients have been col-
lected in four oncology centers in Poland. All molecular 
examinations have been performed in one clinical labora-
tory in Pneumonology, Oncology and Allergology Depart-
ment in Lublin. Five milliliters of blood samples have been 
collected in EDTA-covered tubes. DNA was extracted 
from peripheral blood cells using QIAamp DNA Mini Kit 
(Qiagen, Germany). This study has been approved by the 
Ethics Committee of Medical University in Lublin (No. 
KE-0254/219/2010).
TS and MTHFR genotyping
TS gene VNTR polymorphism was analyzed by poly-
merase chain reaction (PCR) using primers previously 
described by Iacopetta et al. (2001) with further modifica-
tion. The 6-bp deletion on 3′ end of the TS gene and the 
SNP 677C>T in MTHFR gene were analyzed with PCR 
amplification followed by restriction fragment length poly-
morphism analysis (RFLP). Primers for 1494del6 were pre-
viously described by Dotor et al. (2006), whereas MTHFR 
primers were described by Frosst et al. (1995). Restriction 
enzymes used in RFLP reaction were Fermentas FastDigest 
DraI (Thermo Scientific, USA) for TS 1494del6 polymor-
phism and Fermentas FastDigest HinfI (Thermo Scientific, 
USA) for MTHFR 677C>T SNP.
The polymorphism of TS (TSER) VNTR differs accord-
ing to the number of 28-bp repeats and in Caucasian pop-
ulation is most often represented by three genotypes: two 
repeats/two repeats (2R/2R), three repeats/three repeats 
(3R/3R) and heterozygous of 2R/3R.
All PCR reaction products were later visualized on 2 % 
agarose gel with ethidium bromide.
Additionally, Sanger sequencing was used for the vali-
dation of the presence of different polymorphic forms of 
examined genes.
ERCC1 genotyping
ERCC1 SNP (19007C>T) was detected using High Reso-
lution Melt (HRM) method. Amplification of examined 
region and HRM procedure were performed in 48-well 
plates using the Eco Real-Time PCR device (Illumina). 
Table 1  Characteristic of studied group
Factor Characteristics
Whole group (n) 115
Gender
 Male (n, %) 59 (51.3)
 Female (n, %) 56 (48.7)
Age in years (median ± SD) 61 ± 8.5
 ≤61 years (n, %) 50 (43.5)
 >61 years (n, %) 65 (56.5)
Performance status (PS)
 PS = 0 (n, %) 38 (33)
 PS = 1 (n, %) 77 (67)
Weight loss
 <5 % (n, %) 61 (53)
 ≥5 % (n, %) 54 (47)
Anemia
 Yes (n, %) 42 (36.5)
 No (n, %) 73 (63.5)
Smoking status
 Smokers (n, %) 72 (62.6)
 Non-smokers (n, %) 21 (18.3)
 Data not available (n, %) 22 (19.1)
Disease stage
 Inoperable (II–IIIB) (n, %) 29 (25.2)
 Advanced (IV) (n, %) 86 (74.8)
Pathomorphological diagnosis
 Adenocarcinoma (n, %) 106 (92.2)
 Large cell carcinoma (n, %) 8 (7)
 Adenosquamous cell carcinoma (n, %) 1 (0.8)
Prior surgical treatment
 Yes (n, %) 26 (22.6)
 No (n, %) 89 (77.4)
Radiotherapy
 Yes (n, %) 22 (19.1)
 No (n, %) 93 (80.9)




 Cisplatin + pemetrexed (n, %) 108 (93.9)
 Carboplatin + pemetrexed (n, %) 7 (6.1)
Second-line chemotherapy
 Docetaxel (n, %) 10 (8.7)
 Paclitaxel (n, %) 8 (7)
 Erlotinib (n, %) 4 (3.5)
 Crizotinib (n, %) 2 (1.7)
 Belagenpumatucel-L (n, %) 2 (1.7)
 Vinorelbine (n,  %) 5 (4.3)
 Carboplatin + vinorelbine (n, %) 1 (0.9)
 Gemcitabine (n, %) 4 (3.5)
 Cisplatin + gemcitabine (n, %) 2 (1.7)
 Pemetrexed (n, %) 3 (2.6)
 None (n, %) 74 (64.3)
Factor Characteristics
Third-line therapy
 Docetaxel (n) 1
 Gemcitabine (n) 1
 Eribulin (n) 1
 Erlotinib (n) 1
Table 1  continued
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PCR cycling and HRM conditions were performed accord-
ing to Precision™ HRM protocol. Before PCR reaction, 
all examined samples were diluted to the same concentra-
tion of DNA (20 ng/µl) for similar amplification of inves-
tigated gene region and improved quality of HRM. Addi-
tionally, DNA samples with all known allelic variants of 
19000C>T were enrolled as HRM controls. EcoStudy Soft-
ware (Illumina) was used for melt curves analysis. Differ-
ent genotypes of ERCC1 were distinguished according to 
normalization data derived from the raw data plots and dif-
ference graph derived from the normalization data. HRM 
results of ERCC1 SNP analysis was validated by SNaPshot 
technique.
Statistical analysis
Chi square test was used to compare the quantity of 
patients with different response to treatment depending on 
the prevalence of clinical and genetic factors. To compare 
the probability of progression-free survival and overall sur-
vival between the groups with different clinical and molec-
ular factors, the Kaplan–Meier method was used. Cox 
regression model with step-by-step selection was used to 
determine the influence of these factors on progression-free 
survival (PFS) and overall survival (OS) of patients treated 
with platinum and pemetrexed therapy.
Results
The enhancer region of TS gene (TSER) contains a pol-
ymorphic tandem repeat sequence (in our study only 
2 or 3 repeats, 2R or 3R). 22.6 % of non-squamous 
NSCLC patients carried 2R/2R genotype, while 58.3 % 
of patients were heterozygotes 2R/3R, and 19.1 % of 
patients were homozygotes 3R/3R. Guanine nucleotide 
within the second repeat of the 3R alleles was found 
in 34.8 % of examined patients (G>C polymorphism). 
Deletion of 6 bp in 1494 position in both alleles of TS 
gene was described in 7 % of patients, but this deletion 
in only one allele of TS gene—in 37.4 % of patients. 
Rarer T allele in 677C>T MTHFR gene polymorphism 
was observed in 53.9 % of patients. In examined group, 
there were 15.6 % of C/C genotype carriers, 46.1 % of 
C/T genotype and 38.3 % of TT genotype of ERCC1 
gene 19007C>T polymorphism.
The partial remission to first-line chemotherapy with 
platinum compounds and pemetrexed was observed in 
29 patients with non-squamous NSCLC (25.2 %). Stable 
disease was noted in 66 of examined patients (57.4 %) 
and disease progression in 20 patients (17.4 %). Disease 
control rate was noted in 82.6 % of patients. For whole 
group of patients, the median time of progression-free 
survival was 7 months, while the median time of overall 
survival was 14 months.
Some common clinical factors strongly affected the course 
of non-squamous NSCLC in patients treated with platinum 
compounds and pemetrexed in first-line therapy. Patients 
in poor performance status had significantly higher inci-
dence of early progression during first 2 month of treatment 
than patients with good PS. PFS was significantly shorter 
in patients with anemia, body mass loss and in poor perfor-
mance status as compared to patients without these factors. 
Regarding the overall survival of patients treated with plati-
num and pemetrexed, poor performance status, weight loss, 
anemia and lack of second-line treatment had a significant 
negative prognostic value. Stage of disease, gender and age 
had no impact on prognosis in our patients (Table 2).
Several polymorphic variants of TS and MTHFR genes 
were important as a predictor of platinum compounds and 
pemetrexed therapy effectiveness in non-squamous NSCLC 
patients. Polymorphic tandem repeat sequence (2R, 3R) in 
the enhancer region of TS gene (TSER) and a single nucleo-
tide polymorphism (G>C) within the second repeat of the 
3R allele seem to be important for the effectiveness of this 
first-line chemotherapy. We observed insignificant shorten-
ing of PFS in 3R/3R homozygotes as compared to 2R/2R 
homozygotes and 2R/3R heterozygotes. PFS was signifi-
cantly shorter (6 months) in patients carrying synchronous 
3R allele and G nucleotide in the second repeat of 3R allele 
than in carriers of other genotypes of TS gene (Fig. 1).
Early disease progression was observed significantly 
more frequent in patients with T/T genotype than in 
patients with C/C or C/T genotypes of MTHFR 677C>T 
polymorphism. PFS and OS were not affected by MTHFR 
gene polymorphism. However, combined analysis of TS 
VNTR polymorphism and MTHFR 677C>T SNP revealed 
shortening of PSF (5 months) in synchronous carriers of 
3R allele in TS gene and two C alleles in MTHFR gene 
(Table 3, Fig. 2).
Multivariate Cox logistic regression confirmed that the 
strongest factors that increased the risk of progression in 
non-squamous NSCLC patients treated with platinum and 
pemetrexed first-line therapy were poor performance status, 
weight loss, anemia and synchronous presence of 3R allele 
and G nucleotide in the second repeat of 3R allele in TS 
gene. Moreover, clinical prognostic factors: lack of appli-
cation of second-line chemotherapy, weight loss and poor 
performance status as well as the above-mentioned geno-
type of TS gene increased risk of early mortality (Table 4).
Discussion
Pemetrexed with combination of platinum compounds was 
registered to front-line treatment of non-squamous NSCLC 
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patients based on the large phase III clinical trial (Scagli-
otti et al. 2008), where patients randomly received either 
cisplatin plus gemcitabine (n = 862) or cisplatin plus pem-
etrexed (n = 863). Higher response rate occurred in the cis-
platin plus pemetrexed arm (28.6 %) than in cisplatin plus 
gemcitabine arm (22.2 %) in patients with non-squamous 
NSCLC. These patients had a longer OS time and trend 
for a longer PFS time on cisplatin plus pemetrexed (11 
and 5.26 months, respectively) than on cisplatin plus gem-
citabine (10.1 and 4.96 months, respectively). However, 
within the squamous lung cancer patients, the response rate 
and HR for OS as well as PFS favored cisplatin plus gem-
citabine over cisplatin plus pemetrexed (Scagliotti et al. 
2008, 2009, 2011).
Compared to results of Scagliotti et al., our study 
showed similar response rate (25.2 %) on platinum com-
pounds and pemetrexed in non-squamous NSCLC 
patients. However, the duration of PFS (7 months) and OS 
(14 months) in our study was slightly longer than in Scagli-
otti et al. study. In phase III clinical trial, current and for-
mer smokers and squamous cell lung cancer patients had 
significantly higher risk of death compared with never-
smoker and non-squamous NSCLC patients treated with 
cisplatin and pemetrexed. Moreover, results of phase II 
and III clinical trials with pemetrexed indicated factors 
that had statistically significant prognostic impact on sur-
vival, including gender, race, performance status and stage 
of disease (Scagliotti et al. 2008, 2009, 2011). In our study 
in Cox-adjusted analysis, we found several typical clini-
cal factors: poor performance status, weight loss and ane-
mia, which had affected progression and death risk. In 




























































































































































































































































































































Fig. 1  Impact of TS VNTR polymorphism and a single-nucleotide 
polymorphism (G>C) within the second repeat of the 3R allele on the 
progression-free survival in non-squamous NSCLC patients treated 
with platinum and pemetrexed first-line therapy
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of clinical trials concerning pemetrexed therapy. How-
ever, we did not observe the differences of death risk with 
respect to age, smoking status, gender, stage of disease and 
pathomorphological diagnose (adenocarcinoma vs large 
cell carcinoma). The impact of post study therapy on sur-
vival is difficult to evaluate because all studies permitted 
subsequently treatment at the discretion of the oncologists 
(Scagliotti et al. 2009). However, 35.7 % of our platinum 
plus pemetrexed-treated patients received an additional 
line of therapy, which resulted in prolongation of survival 
time to 21 months. We have to remember that these patients 
were in a better performance status than patients without 
possibility of second-line treatment.
Although the effectiveness of chemotherapy, there was 
a group of patients with early progression on platinum 
plus pemetrexed treatment (17.4 % in our study). Clinical 
factors are usually failed for precise prediction of treatment 
benefit. As for today, there are no well-defined molecu-
lar markers that are used in qualification to platinum and 
pemetrexed therapy in lung cancer patients. One of the 
best known is the relationship between the expression of 
ERCC1, TS, DHFR, GARFT, MTHFR as well as ERCC1 
enzymes and the effectiveness of platinum and pemetrexed 
chemotherapy (Lee et al. 2013; Bukhari and Goudar 2013). 
However, the impact of the polymorphisms of genes encod-
ing these enzymes in the efficacy of such chemotherapy is 
poorly described in NSCLC patients.
Li et al. (2013) had examined 45 advanced adenocar-
cinoma patients treated with cisplatin and pemetrexed. 
Median PFS was longer (6.8 vs 3.8 months) for carriers of 
TS genotypes, leading to TS expression reduction (2R/2R, 
2R/3R(C) or 3RC/3R(C) in contrast to the patients with 
genotypes related to the high TS expression (2R/3R(G), 
3R(C)/3R(G) or 3R(G)/3R(G). This TS gene polymorphism 
had predicted the response rate. However, no difference 
in OS was observed (10.3 vs 10.1 months, respectively). 
Moreover, the PFS and OS did not differ between the 
patients with different MTHFR genotypes.
In Hu et al. (2012) study, 90 advance Asian lung can-
cer patients received pemetrexed with platinum regimens 
as first-line treatment or a single-agent treatment in second 
line or further. The variable number of tandem repeat in 
5′-UTR region of TS gene and deletion/insertion polymor-
phism in 3′-UTR region of TS gene was analyzed. Disease 
control rate, objective response rate and PFS were similar 
between patients harboring 2R and 3R alleles as well as 
alleles containing 6-bp deletion or insertion. The authors 
did not observe any combined effect of both TS polymor-
phisms on clinical outcome of patients treated with peme-
trexed-based therapy (Hu et al. 2012).
Wang et al. (2013) revealed that Chinese patients with 
the deletion in both 3′-UTR regions of TS gene (−/− 6 bp) 
had significantly longer PFS and OS time than patients 
Fig. 2  Impact of TS VNTR polymorphism and MTHFR gene 
677C>T polymorphism on the progression-free survival in non-squa-
mous NSCLC patients treated with platinum and pemetrexed first-
line therapy
Table 4  The multivariate Cox 
logistic regression of factors 
affecting the progression-free 
survival and overall survival 
of non-squamous NSCLC 
patients treated with platinum 
compounds and pemetrexed in 
first-line chemotherapy
Factor β p value Hazard ratio [95 % CI]
Progression-free survival
 Poor performance status 0.8504 0.0008 2.3405 [1.4249–3.8444]
 Lack of radiotherapy 0.6185 0.0361 1.8561 [1.0439–3.3004]
 2R/3R(G) or 3R(C)/3R(G) or 3R(G)/3R(G) of TS genotype 0.5043 0.0249 1.6558 [1.0681–2.5668]
 Anemia 0.4731 0.046 1.6049 [1.0108–2.5482]
Overall model fit: p < 0.0001; χ2 = 26,632
Overall survival
 Lack of second-line treatment 1.1864 0.0008 3.2752 [1.6421–6.5323]
 2R/3R(G) or 3R(C)/3R(G) or 3R(G)/3R(G) of TS genotype 0.7273 0.022 2.0696 [1.1141–3.8445]
 Weight loss <5 % 0.7257 0.0153 2.0662 [1.1525–3.7042]
 Poor performance status 0.6534 0.0468 1.9221 [1.0126–3.6486]
Overall model fit: p < 0.0001; χ2 = 29,974
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with insertion at least in one of 3′-UTR region (−/+ 6 bp) 
after short-term pemetrexed treatment (Wang et al. 2013).
In contrast to above cited studies, Arvealo et al. (Arévalo 
et al. 2014) had examined only 25 Caucasian patients 
treated with pemetrexed-based regimens. Authors showed 
that the presence of 3R/3R genotype significantly corre-
lated with a superior response rate compared to presence 
of 2R/2R, 2R/3R and 3R/4R genotypes. Moreover, a trend 
toward a better PFS and significant superior OS was found 
among subjects showing 3R/3R genotype. Active or former 
smokers who were homozygous for insertion (+/+ 6 bp) in 
3′-UTR TS region and had higher expression of TS, signifi-
cantly more frequent responded to treatment than patients 
who were heterozygous +/+ 6 bp (Arévalo et al. 2014).
Polymorphisms of TS (both 5′-UTR VNTR and G>C 
polymorphism within the third VNTR) and MTHFR genes 
were tested in large study (127 Caucasian patients with 
complete gene polymorphisms analysis), which evaluated 
the effectiveness of pemetrexed plus carboplatin or pem-
etrexed chemotherapy. PFS was not different for patients 
with different TS genotypes. However, carriers of TT geno-
type in MTHFR gene had longer PFS time compared with 
patients with CC or CT genotypes of this gene (Smit et al. 
2009).
Our multicenter study is one of the largest involving a 
homogeneous group of Caucasian, non-squamous NSCLC 
patients treated with front-line chemotherapy based on 
pemetrexed and platinum and who had simultaneous anal-
ysis of up to five different polymorphisms in TS, MTHFR 
and ERCC1 genes. It should be noted that “high-expres-
sion” genotype of TS gene (2R/3R(G), 3R(C)/3R(G) or 
3R(G)/3R(G) in opposition to “low-expression” genotype 
of this gene (2R/2R, 2R/3R(C) or 3RC/3R(C) had strong 
negative predictive value for NSCLC patients treated with 
platinum compounds and pemetrexed. The predictive role 
of MTHFR gene polymorphism was not clear (carriers of 
TT genotype of MTHFR gene significantly more frequently 
responded to chemotherapy). However, according to our 
results and results of Smit et al. (2009), co-occurrence of 
CC genotype of MTHFR gene and 3R allele in 5′-UTR 
region of TS gene could be assumed as negative predic-
tive factor for pemetrexed-based chemotherapy. Whereas, 
ERCC1 gene polymorphism may not predict the effective-
ness of this chemotherapy. Moreover, the data concerning 
relation between the ERCC1 expression and/or ERCC1 
SNP and the effectiveness of chemotherapy are debatable 
(Friboulet et al. 2013). Therefore, the predictive value of 
ERCC1 SNP for platinum-based therapy is not so obvious. 
It appears that the gene polymorphisms, whose expression 
could affect the pemetrexed’ effectiveness, are stronger pre-
dictors for this type of treatment.
Unfortunately, clinical application of polymorphism 
analysis in qualification to platinum and pemetrexed 
chemotherapy has limitation as a lack of prospective clini-
cal trials results (e.g., JMEN). Moreover, these prospective 
clinical trials should contain more than one chemotherapy 
arms, e.g., comparison of platinum and gemcitabine chem-
otherapy with platinum and pemetrexed administrated 
according to gene signature.
Conflict of interest None declared.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
Al-Saleh K, Quinton C, Ellis PM (2012) Role of pemetrexed in 
advanced non-small-cell lung cancer: meta-analysis of rand-
omized controlled trials, with histology subgroup analysis. Curr 
Oncol 19(1):e9–e15
Arévalo E, Castañón E, López I et al (2014) Thymidylate synthase 
polymorphisms in genomic DNA as clinical outcome predictors 
in a European population of advanced non-small cell lung cancer 
patients receiving pemetrexed. J Transl Med 12(1):98
Bukhari AA, Goudar RK (2013) Thymidylate synthase as predictive 
biomarker for pemetrexed response in NSCLC. Lung Cancer 
Inter 436409:1–7
Ceppi P, Volante M, Saviozzi S et al (2006) Squamous cell carcinoma 
of the lung compared with other histotypes shows higher mes-
senger RNA and protein levels for thymidylate synthase. Cancer 
107(7):1589–1596
Chattopadhyay S, Moran RG, Goldman D (2007) Pemetrexed: 
biochemical and cellular pharmacology. Mol Cancer Ther 
6(2):404–417
Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemi-
ology, etiology, and prevention. Clin Chest Med 32:605–644
Dotor E, Cuatrecases M, Martínez-Iniesta M et al (2006) Tumor thy-
midylate synthase 1494del6 genotype as a prognostic factor in 
colorectal cancer patients receiving fluorouracil-based adjuvant 
treatment. J Clin Oncol 24(10):1603–1611
Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform 
expression and DNA repair in non-small-cell lung cancer. N Engl 
J Med 368:1101–1110
Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk fac-
tor for vascular disease: a common mutation in methylenetetrahy-
drofolate reductase. Nat Genet 10(1):111–113
Gazdar AF (2007) DNA repair and survival in lung cancer—the two 
faces of Janus. N Engl J Med 356(8):771–773
Hanauske AR, Eismann U, Oberschmidt O et al (2007) In vitro che-
mosensitivity of freshly explanted tumor cells to pemetrexed 
is correlated with target gene expression. Invest New Drugs 
25:417–423
Hu Q, Li X, Su C et al (2012) Correlation between thymi-
dylate synthase gene polymorphisms and efficacy of pem-
etrexed in advanced non-small cell lung cancer. Exp Ther Med 
4(6):1010–1016
Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism 
in the enhancer region of the thymidylate synthase promoter 
influences the survival of colorectal cancer patients treated with 
5-fluorouracil. Br J Cancer 85(6):827–830
Kawakami K, Watanabe G (2003) Identification and func-
tional analysis of single nucleotide polymorphism in the 
2057J Cancer Res Clin Oncol (2014) 140:2047–2057 
1 3
tandem repeat sequence of thymidylate synthase gene. Cancer 
Res 63:6004–6007
Kumar K, Vamsy M, Jamil K (2010) Thymidylate synthase gene poly-
morphisms effecting 5-FU response in breast cancer patients. 
Cancer Biomark 6(2):83–93
Lee SH, Noh KB, Lee JS et al (2013) Thymidylate synthase and 
ERCC1 as predictive markers in patients with pulmonary adeno-
carcinoma treated with pemetrexed and cisplatin. Lung Cancer 
81(1):102–108
Li WJ, Jiang H, Fang XJ et al (2013) Polymorphisms in thymidylate 
syntase and reduced folate carrier (SLC19A1) genes predict sur-
vival outcome in advanced non-small cell lung cancer patients 
treated with pemetrexed-based chemotherapy. Oncol Lett 
5(4):1165–1170
Mandola MV, Stoehlmacher J, Muller-Weeks S et al (2003) A novel 
single nucleotide polymorphism within the 5′ tandem repeat 
polymorphism of the thymidylate synthase gene abolishes 
USF-1 binding and alters transcriptional activity. Cancer Res 
63(11):2898–2904
Mandola MV, Stoehlmacher J, Zhang W et al (2004) A 6 bp poly-
morphism in the thymidylate synthase gene causes message 
instability and is associated with decreased intratumoral TS 
mRNA levels. Pharmacogenetics 14:319–327
Mlak R, Krawczyk P, Ramlau R et al (2013) Predictive value of 
ERCC1 and RRM1 gene single-nucleotide polymorphisms for 
first-line platinum- and gemcitabine-based chemotherapy in non-
small cell lung cancer patients. Oncol Rep 30(5):2385–2398
Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study com-
paring cisplatin plus gemcitabine with cisplatin plus pemetrexed 
in chemotherapy-naive patients with advanced-stage non-small-
cell lung cancer. J Clin Oncol 26:3543–3551
Scagliotti G, Hanna N, Fossella F et al (2009) The differential effi-
cacy of pemetrexed according to NSCLC histology: a review of 
two phase III studies. Oncologist 14(3):253–263
Scagliotti G, Brodowicz T, Shepherd FA et al (2011) Treatment-by-
histology interaction analyses in three phase III trials show supe-
riority of pemetrexed in nonsquamous non-small cell lung cancer. 
J Thorac Oncol 6:64–70
Sculier JP, Moro-Sibilot D (2009) First- and second-line therapy for 
advanced non-small cell lung cancer. Eur Respir J 33:915–930
Smit EF, Burgers SA, Biesma B et al (2009) Randomized phase II and 
pharmacogenetic study of pemetrexed compared with pemetrexed 
plus carboplatin in pretreated patients with advanced non–small-
cell lung cancer. J Clin Oncol 27(12):2038–2045
Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2013) Effect of 
the methylenetetrahydrofolate reductase C677T polymorphism 
on chemosensitivity of colon and breast cancer cells to 5-fluoro-
uracil and methotrexate. J Natl Cancer Inst 96(2):134–144
Stoehlmacher J, Goekkurt E, Hoeffken G et al (2009) Thymidylate 
synthase polymorphisms and immunohistochemistry in non-
small cell lung cancer. J Clin Oncol 27(suppl):11101
Tiseo M, Giovannetti E, Tibaldi C et al (2012) Pharmacogenetic study 
of patients with advanced non-small cell lung cancer (NSCLC) 
treated with second-line pemetrexed or pemetrexed-carboplatin. 
Lung Cancer 78(1):92–99
Uchida K, Hayashi K, Kawakami K et al (2004) Loss of heterozy-
gosity at the thymidylate synthase (TS) licus on chromosome 
18 affects tumor response and survival in individuals heterozy-
gous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 
10:433–439
Wang X, Wang Y, Wang Y, Cheng J, Wang Y, Ha M (2013) Asso-
ciation of thymidylate synthase gene 3′-untranslated region 
polymorphism with sensitivity of non-small cell lung cancer to 
pemetrexed treatment: TS gene polymorphism and pemetrexed 
sensitivity in NSCLC. J Biomed Sci 25(20):5
Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H (2014) The pem-
etrexed-containing treatments in the non-small cell lung cancer, 
is −/low thymidylate synthase expression better than +/high 
thymidylate synthase expression: a meta-analysis. BMC Cancer 
19(14):205
Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G (2007) DNA 
synthesis and repair genes RRM1 and ERCC1 in lung cancer. N 
Engl J Med 356(8):800–808
